Back

Cost-effectiveness of AF ablation versus medical therapy for the treatment of atrial fibrillation and heart failure.

11 May 2024 (09:00 - 09:45)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation 1 Heart Failure in Atrial Fibrillation HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Professor Mark Gallagher

St George's University Hospital NHS Foundation Trust, London (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
Gender differences in atrial cardiomyopathy: insights from patients with atrial fibrillation
Doctor R. Teixeira (Vila Nova de Gaia, PT)
Abstract Slides Video
Presentation thumbnail
Biophysical parameters of pulmonary vein isolation with very high-power short-duration compared to conventional radiofrequency ablation guided by ablation index
Doctor R. Teixeira (Vila Nova de Gaia, PT) Doctor F. Duarte (Ponta Delgada, PT)
Abstract Slides Video
Presentation thumbnail
Role of combined pulmonary vein isolation with left atrial ganglionated plexus ablation in paroxysmal atrial fibrillation and sinus bradycardia
Doctor S. Paula (Barreiro, PT)
Abstract Slides Video
Presentation thumbnail
Effects of atrial fibrillation ablation in patients with heart failure: a systematic review and meta-analysis
Doctor A. Buongiorno (Genoa, IT)
Abstract Slides Video
Presentation thumbnail
Association of elevated LV filling pressure and development of LV systolic dysfunction in lone atrial fibrillation
Professor S. Ryu (Seoul, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial fibrillation 1

The Event

Event poster

Heart Failure 2024

11 May 2024 09:00 CET
You may be interested in
thumbnail
Congress Presentation
Catheter ablation: pros and cons
thumbnail
Congress Presentation
NET-COST-HFrEF: A NETwork meta-analysis with COST-effectiveness evaluation in HFrEF
thumbnail
Congress Presentation
An economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from a Danish healthcare perspective

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources